|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 487/04 | (2006.01) |
| C07D 487/04 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 31/519 | (2006.01) |
| (11) | Number of the document | 4043466 |
| (13) | Kind of document | T |
| (96) | European patent application number | 22165237.3 |
| Date of filing the European patent application | 2019-01-29 | |
| (97) | Date of publication of the European application | 2022-08-17 |
| (45) | Date of publication and mention of the grant of the patent | 2024-08-21 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201862624176 P | 2018-01-31 | US | |
| 201862672701 P | 2018-05-17 | US | |
| 201862747736 P | 2018-10-19 | US |
| (72) |
MARX, Matthew, Arnold , US
LEE, Matthew, Randolph , US
BOBINSKI, Thomas, P. , US
BURNS, Aaron, Craig , US
ARORA, Nidhi , US
CHRISTENSEN, James, Gail , US
KETCHAM, John. Michael , US
|
| (73) |
Mirati Therapeutics, Inc. ,
Route 206 and Province Line Road, Princeton, New Jersey 08543,
US
|
| (54) | PRC2 INHIBITORS |
| PRC2 INHIBITORS |